<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657537</url>
  </required_header>
  <id_info>
    <org_study_id>H-18010656</org_study_id>
    <nct_id>NCT03657537</nct_id>
  </id_info>
  <brief_title>Effects of Ketone Bodies on Cognition in Type 2 Diabetes</brief_title>
  <acronym>KETOCOGNITION</acronym>
  <official_title>KETOCOGNITION - Effects of Ketone Bodies on Cognition in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Psychiatric Centre Rigshospitalet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes negatively affects cognition and increases the risk of developing overt dementia.&#xD;
      Decreased cerebral glucose metabolism may be contributing to this effect, thus providing a&#xD;
      glucose substitute using ketone bodies might improve neuronal function.&#xD;
&#xD;
      In this study the investigators propose to provide quantitative results on cognitive&#xD;
      performance during acute hyperketonemia in patients with type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been proposed that hypometabolism in the brain contributes to the neuropathology that&#xD;
      leads to Alzheimer's disease (AD). Additionally cognitive disturbances in patients with AD&#xD;
      are associated with and paralleled by a decrease in cerebral glucose metabolism. This AD-like&#xD;
      reduction in cerebral metabolism has also been associated with insulin-resistance, and may&#xD;
      contribute to one of the links between diabetes and AD. Therefore manipulating&#xD;
      neuro-energetics by providing a glucose substitute seems to be a means of improving neuronal&#xD;
      function.&#xD;
&#xD;
      Here the investigators will examine the effect of ketone bodies on cognitive performance in&#xD;
      patients with type 2 diabetes by a randomized cross-over trial. Each subject will meet for&#xD;
      two experimental visits separated by 2-6 weeks. During the two visit days subjects will, in a&#xD;
      randomized order, receive ketone bodies (β-hydroxybutyrate) or placebo (saline)&#xD;
      intravenously. On both test days plasma glucose levels will be clamped. After glucose levels&#xD;
      have been stabilized cognitive performance will be assessed by a battery of validated&#xD;
      cognitive tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Actual">February 14, 2019</completion_date>
  <primary_completion_date type="Actual">February 14, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive composite score (global score)</measure>
    <time_frame>When glucose levels have been stabilized for 40 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symbol Digit Modalities Test (SDMT)</measure>
    <time_frame>When glucose levels have been stabilized for 40 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Type2 Diabetes</condition>
  <condition>Ketonemia</condition>
  <condition>Cognitive Change</condition>
  <arm_group>
    <arm_group_label>Hyperketonemia - Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are randomly assigned to initially receive ketone infusion and then saline infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Hyperketonemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are randomly assigned to initially receive saline infusion and then ketone infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketone infusion</intervention_name>
    <description>β-hydroxybutyrate is infused intravenously.</description>
    <arm_group_label>Hyperketonemia - Placebo</arm_group_label>
    <arm_group_label>Placebo - Hyperketonemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline infusion</intervention_name>
    <description>saline is infused intravenously.</description>
    <arm_group_label>Hyperketonemia - Placebo</arm_group_label>
    <arm_group_label>Placebo - Hyperketonemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed and written consent&#xD;
&#xD;
          -  Clinically diagnosed type 2 diabetes mellitus for at least 3 months (diagnosed&#xD;
             according to the criteria of the World Health Organization (WHO)).&#xD;
&#xD;
          -  Normal haemoglobin ≥ 8.0 mmol/L (male) or ≥ 6.4 mmol/L (female)&#xD;
&#xD;
          -  Male or female participants aged 35-70 years, both inclusive.&#xD;
&#xD;
          -  Treated with diet or any antidiabetic medication except insulin and SGLT2i within the&#xD;
             last 3 weeks.&#xD;
&#xD;
          -  HbA1c ≤ 9.5 % by local laboratory analysis.&#xD;
&#xD;
          -  BMI &gt; 23 kg/m2 and &lt; 35 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of any investigational medicinal product within 3 months prior to screening.&#xD;
&#xD;
          -  Liver disease (alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase&#xD;
             (ASAT) &gt;2 times normal values) or history of hepatobiliary disorder.&#xD;
&#xD;
          -  Nephropathy (serum creatinine levels ≥ 126 μmol/L (male) or ≥ 111 μmol/L (female)).&#xD;
&#xD;
          -  Cardiac problems defined as decompensated heart failure (New York Heart Association&#xD;
             (NYHA) class III and IV) at any time and/or angina pectoris within the last 12 months&#xD;
             and/or acute myocardial infarction at any time.&#xD;
&#xD;
          -  Active or recent malignant disease.&#xD;
&#xD;
          -  Treatment with drugs that cannot be paused for 12 hours.&#xD;
&#xD;
          -  Repeated resting blood pressure at screening outside the range 90-150 mmHg for&#xD;
             systolic or 50-100 mmHg for diastolic. This exclusion criterion also pertains to&#xD;
             subjects taking antihypertensives.&#xD;
&#xD;
          -  Inability to perform cognitive tests as assessed by the investigators (e.g. visual or&#xD;
             auditory impairment).&#xD;
&#xD;
          -  Known abnormalities of the central nervous system or any endocrinological (with the&#xD;
             exception of diabetes mellitus and euthyroid goiter), haematological, neurological,&#xD;
             psychiatric diseases or other major disorders that in the opinion of the investigator&#xD;
             precludes compliance with the protocol, evaluation of the results or represent an&#xD;
             unacceptable risk for the participant's safety.&#xD;
&#xD;
          -  Proliferative retinopathy (funduscopy performed within 12 months before the screening&#xD;
             is acceptable) and/or severe neuropathy.&#xD;
&#xD;
          -  Current treatment with systemic drugs, which may interfere with glucose metabolism.&#xD;
&#xD;
          -  Significant history of alcoholism or drug/chemical abuse as per investigator's&#xD;
             judgement.&#xD;
&#xD;
          -  Current tobacco user (smoking or nicotinic product use 3 months prior to screening).&#xD;
&#xD;
          -  Severe hypoglycaemic event during the past 6 months.&#xD;
&#xD;
          -  Known hypoglycaemia unawareness.&#xD;
&#xD;
          -  Participants with mental incapacity or language barriers precluding adequate&#xD;
             understanding or co-operation or who, in the opinion of the investigator or their&#xD;
             general practitioner, should not participate in the trial.&#xD;
&#xD;
          -  For females only: Pregnancy, breast-feeding status or intention of becoming pregnant&#xD;
             during the trial.&#xD;
&#xD;
          -  Any chronic disorder or severe disease that in the opinion of the investigator might&#xD;
             endanger participant's safety or compliance with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Research in Endocrinology, Bispebjerg University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>February 19, 2019</last_update_submitted>
  <last_update_submitted_qc>February 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Nicole Jacqueline Jensen</investigator_full_name>
    <investigator_title>Clinical research assistant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Ketosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

